Navigation Links
USPTO Confirms Validity of Bystolic(R) Patent
Date:11/24/2008

NEW YORK, Nov. 24, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) announced today that the U.S. Patent and Trademark Office ("USPTO") has closed prosecution on the merits of the reexamination proceedings for the patent for Bystolic(R) and confirmed the validity of all of the previously granted claims. As a result, the USPTO has issued a Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Patent No. 6,545,040 (the '040 patent) to Janssen Pharmaceutica N.V., the patent holder. The Notice withdraws all of the enumerated rejections and confirms such validity. The '040 patent covers nebivolol, the active ingredient in Bystolic(R), a beta-blocker that is currently approved in the United States for the treatment of hypertension. The '040 patent expires in April 2020. Forest has applied for patent term extension for this patent until December 2021.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

About the Bystolic(R) License

Forest licensed U.S. and Canadian rights to nebivolol from Mylan Laboratories Inc. in January 2006. Forest markets nebivolol under the Bystolic trademark in the U.S. Mylan licensed the U.S. and Canadian rights to nebivolol from Janssen Pharmaceutica N.V. in February 2001, and has obtained Janssen's consent to sub-license nebivolol to Forest Laboratories in those territories.

About Forest Laboratories

Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. USPTO Issues Patent Embodying Methodologies for Abating a Broad Range of Allergens, Pathogens, Viruses, Bacteria, Odors and Volatile Organic Compounds.
2. Gentiva Health Services Confirms Management Succession
3. Study confirms increased heart attack deaths in NYC ambulance diversions
4. Report Confirms Consumer Selection is a Driving Force in Health Care Today
5. Breaking News: Finally! A Catholic Bishop Confirms that a Catholic Cannot Vote for Obama in Good Conscience
6. Study Confirms Effectiveness of Magnetic Therapy in Pain Relief
7. New Study Confirms Link Between Pain Pumps and Cartilage Damage -- Searcy Denney Law Firm Investigates Claims
8. Longs Drug Stores Confirms Receipt of Expression of Interest from Walgreens
9. Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model
10. Study confirms colorectal cancer screening should start at age 50
11. Pennsylvania Department of Health Confirms Rabid Kitten Found in York County
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2017)... ... 2017 , ... Getting earned media coverage meaningful for Garden Media Group's clients ... the year, Garden Media aims to provide material helpful to clients’ goals and bottom ... client’s key messages to gain coveted media placements, Garden Media wows clients year-round. ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... from third world countries to hospitals in the United States, it’s a threat ... on the current obstacles facing infection prevention and offers strategies for the healthcare ...
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards for eating ... of disordered eating, announced today that the 2017 Symposium set a new attendance record ... countries converged on the Green Valley Resort in Las Vegas. , “We are ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 24, 2017 Abdominal Aortic Aneurysm Repair Devices Market was ... 2022, Globally, registering a CAGR of 5.1% from 2016 to 2022. The endovascular stent ... dominate the market during the study period. Continue Reading ... ... ...
(Date:3/24/2017)... 2017 New England Pediatric Device Consortium (NEPDC) ... including funding and in-kind service towards the commercialization of ... "Making blood draws less traumatic for children could ... experience better.  We,re looking forward to working with Velano ... care for the kids we treat," said Ann-Christine ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global Wound ... report to their offering. ... The global wound care market was worth $24,482.9 million in 2015 and ... Among the various wound care products type, the advanced wound ... 2015. Among the various applications, surgical wound segment held the largest share ...
Breaking Medicine Technology: